• Colgate-Palmolive recently announced a four-year collaboration with the WHO Foundation to fund initiatives that expand oral health education, integrate oral care into national health systems, and elevate oral health as a public health priority worldwide.
• This partnership underscores how corporate funding can influence global health policy and further embed oral care within broader primary healthcare agendas.
• Next, we’ll examine how Colgate-Palmolive’s long-term WHO Foundation partnership, centered on integrating oral health into national systems, informs its investment narrative.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

What Is Colgate-Palmolive's Investment Narrative?

To own Colgate-Palmolive, you need to be comfortable with a mature, global consumer brand that offers modest growth, a reliable dividend and active capital returns, but at a valuation that screens richer than many household peers. Near term, the key catalysts remain Q4 2025 results on January 30 and any updates to 2026 guidance, especially around input costs, FX and how management balances buybacks with its high debt load. The new four-year WHO Foundation collaboration fits more into the brand and policy story than the earnings story: it strengthens Colgate’s role in shaping oral health standards and education globally, but is unlikely to move revenue or profit meaningfully in the short run. That said, it may reinforce the “defensive” narrative some analysts already see driving recent share price enthusiasm.

However, investors should not overlook how Colgate’s high debt can amplify both returns and risks. Colgate-Palmolive's shares have been on the rise but are still potentially undervalued by 32%. Find out what it's worth.

Exploring Other Perspectives

Four Simply Wall St Community members see Colgate’s fair value between US$87 and about US$123, a wide span that reflects very different growth and risk assumptions. Set that against recent analyst caution around input cost and currency pressures and you can see why it pays to compare several viewpoints before deciding how dependable Colgate’s current performance really feels.

Explore 4 other fair value estimates on Colgate-Palmolive - why the stock might be worth just $87.00!

Build Your Own Colgate-Palmolive Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.